Pilot Study of the Treatment of Erectile Dysfunction (ED) With Extracorporeal Shockwave Therapy (ESWT)
Launched by STORZ MEDICAL AG · Feb 20, 2014
Trial Information
Current as of August 02, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Erectile dysfunction for more than 6 months
- • Informed consent
- • Positive effect of phosphodiesterase type 5 inhibitor (PDE5i)
- • IIEF-15 score less than 20
- • No neurological disease
- • Stable partnership for more than 3 months
- • Age 18-75
- Exclusion Criteria:
- • Total prostatectomy
- • Another reason for ED except for vascular disorder
- • Clinically significant hematological disease
- • Heart stroke, Arrythmia during the last 6 months
- • Cancer during the last 5 years
- • Intake of antiandrogen
- • ED treatment with the last 7 days
- • IIEF score higher than, equal to 20
- • Previous shockwave treatment
About Storz Medical Ag
Storz Medical AG is a leading innovator in the field of medical technology, specializing in the development and manufacturing of advanced therapeutic devices and systems. With a strong emphasis on non-invasive treatments, the company harnesses cutting-edge technologies to enhance patient care and improve clinical outcomes. Committed to quality and excellence, Storz Medical AG collaborates closely with healthcare professionals and research institutions to advance medical science, particularly in areas such as urology, orthopedics, and aesthetics. Through its robust portfolio of clinical trials, the company aims to validate and expand the applications of its pioneering solutions in diverse medical settings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chemnitz, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials